Correction: "Cell-typedependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia [31, 9, (1870-1884), (2011)]DOI: https://doi.org/10.1128/MCB.01393-10;Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia

Molecular and Cellular Biology

Volumn 31, Issue 9, 2011, Pages 1870-1884

  Wolff, Nicholas C ^a,b,c   Vega Rubin de Celis, Silvia ^a,b,c   Xie, Xian Jin ^b,c   Castrillon, Diego H ^a,c   Kabbani, Wareef ^a   Brugarolas, James ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE LKB1;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL TYPE; FIBROBLAST; HYPOXIA; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE;

RAPTORES;

EID: 79955389182     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00224-17     Document Type: Erratum

References (69)

1. Abraham, R. T., and C. H. Eng. 2008. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin. Ther. Targets 12:209-222.
2. Arsham, A. M., J. J. Howell, and M. C. Simon. 2003. A novel hypoxiainducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278:29655-29660.
3. Avruch, J., et al. 2009. Amino acid regulation of TOR complex 1. Am. J. Physiol. Endocrinol. Metab. 296:E592-E602.
4. Bain, J., et al. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408:297-315.
5. Reference deleted
6. Brafman, A., et al. 2004. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest. Ophthalmol. Vis. Sci. 45:3796-3805.
7. Brugarolas, J. 2010. mTORC1 signaling and hypoxia, p. 75-97. In V. A. A. Polunovsky and P. J. J. Houghton (ed.), mTOR pathway and mTOR inhibitors in cancer therapy. Humana Press, Totawa, NJ.
8. Brugarolas, J., and W. G. Kaelin, Jr. 2004. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6:7-10.
9. Brugarolas, J., et al. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18:2893-2904.
10. Cai, S. L., et al. 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol. 173:279-289.
11. Connolly, E., S. Braunstein, S. Formenti, and R. J. Schneider. 2006. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol. Cell. Biol. 26:3955-3965.
12. Corradetti, M. N., K. Inoki, and K. L. Guan. 2005. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J. Biol. Chem. 280:9769-9772.
13. Crino, P. B., K. L. Nathanson, and E. P. Henske. 2006. The tuberous sclerosis complex. N. Engl. J. Med. 355:1345-1356.
14. Dayan, F., et al. 2009. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway. J. Cell. Physiol. 218:167-174.
15. DeYoung, M. P., P. Horak, A. Sofer, D. Sgroi, and L. W. Ellisen. 2008. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22:239-251.
16. Dufner, A., and G. Thomas. 1999. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res. 253:100-109.
17. Fonseca, B. D., E. M. Smith, V. H. Lee, C. MacKintosh, and C. G. Proud. 2007. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem. 282: 24514-24524.
18. Garcia-Maceira, P., and J. Mateo. 2009. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28:313-324.
19. Gery, S., et al. 2007. RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. Exp. Hematol. 35:572-578.
20. Gwinn, D. M., et al. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30:214-226.
21. Hahn, W. C., et al. 2002. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22:2111-2123.
22. Hara, K., et al. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189.
23. Hardie, D. G. 2007. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8:774-785.
24. Hawley, S. A., et al. 2003. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMPactivated protein kinase cascade. J. Biol. 2:28.
25. Horton, J. D., H. Shimano, R. L. Hamilton, M. S. Brown, and J. L. Goldstein. 1999. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103:1067-1076.
26. Inoki, K., et al. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968.
27. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
28. Jin, H. O., et al. 2007. Hypoxic condition-and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal. 19:1393-1403.
29. Kalender, A., et al. 2010. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:390-401.
30. Kaper, F., N. Dornhoefer, and A. J. Giaccia. 2006. Mutations in the PI3K/ PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 66:1561-1569.
31. Kim, C. J., et al. 2004. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur. J. Cancer 40:136-141.
32. Kim, D. H., et al. 2002. mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell 110:163-175.
33. Kim, D. H., et al. 2003. GbetaL, a positive regulator of the rapamycinsensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11:895-904.
34. Reference deleted
35. Kucejova, B., et al. 10 January 2011. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene doi:10.1038/onc.2010.587. [Epub ahead of print.]
36. Kuhn, R., F. Schwenk, M. Aguet, and K. Rajewsky. 1995. Inducible gene targeting in mice. Science 269:1427-1429.
37. Kwiatkowski, D. J., et al. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11:525-534.
38. Lee, S. J., R. Feldman, and P. H. O'Farrell. 2008. An RNA interference screen identifies a novel regulator of target of rapamycin that mediates hypoxia suppression of translation in Drosophila S2 cells. Mol. Biol. Cell 19:4051-4061.
39. Li, S., et al. 2008. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc. Natl. Acad. Sci. U. S. A. 105:3539-3544.
40. Liu, L., et al. 2006. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21:521-531.
41. Loewith, R., et al. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10:457-468.
42. Ma, X. M., and J. Blenis. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318.
43. Magagnin, M. G., et al. 2008. The mTOR target 4E-BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics 8:1019-1028.
44. Nakau, M., et al. 2002. Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res. 62:4549-4553.
45. Oshiro, N., et al. 2007. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 282:20329-20339.
46. Peterson, T. R., et al. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873-886.
47. Pineau, P., et al. 2010. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 107:264-269.
48. Reiling, J. H., and E. Hafen. 2004. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18:2879-2892.
49. Reference deleted
50. Sancak, Y., et al. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25:903-915.
51. Sanchez-Cespedes, M., et al. 2002. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62:3659-3662.
52. Schneider, A., R. H. Younis, and J. S. Gutkind. 2008. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 10:1295-1302.
53. Schwarzer, R., et al. 2005. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 24:1138-1149.
54. Shaw, R. J., et al. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99.
55. Shoshani, T., et al. 2002. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22:2283-2293.
56. Shumway, S. D., Y. Li, and Y. Xiong. 2003. 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J. Biol. Chem. 278:2089-2092.
57. Sofer, A., K. Lei, C. M. Johannessen, and L. W. Ellisen. 2005. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell. Biol. 25:5834-5845.
58. Sonenberg, N., and A. G. Hinnebusch. 2009. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136:731-745.
59. Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21:70-71.
60. Stroka, D. M., et al. 2001. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 15:2445-2453.
61. Thedieck, K., et al. 2007. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2:e1217.
62. Tiainen, M., A. Ylikorkala, and T. P. Makela. 1999. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc. Natl. Acad. Sci. U. S. A. 96:9248-9251.
63. Tinton, S. A., and P. M. Buc-Calderon. 1999. Hypoxia increases the association of 4E-binding protein 1 with the initiation factor 4E in isolated rat hepatocytes. FEBS Lett. 446:55-59.
64. Vander Haar, E., S. I. Lee, S. Bandhakavi, T. J. Griffin, and D. H. Kim. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9:316-323.
65. Vega-Rubin-de-Celis, S., et al. 2010. Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry 49: 2491-2501.
66. Wang, L., T. E. Harris, R. A. Roth, and J. C. Lawrence, Jr. 2007. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem. 282:20036-20044.
67. Reference deleted
68. Yabe, D., R. Komuro, G. Liang, J. L. Goldstein, and M. S. Brown. 2003. Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc. Natl. Acad. Sci. U. S. A. 100:3155-3160.
69. Zeqiraj, E., B. M. Filippi, M. Deak, D. R. Alessi, and D. M. van Aalten. 2009. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326:1707-1711.